Basmisanil

N/A

Report date: 2025/02/25 16:20:12
NME

Base Information

Drug NameBasmisanil
Drug Alias NameGABRA5 negative allosteric modulator (NAM) - Roche巴米沙尼basmisanilbasmisanilumRO5186582 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor alpha-5 inverse agonists
TargetsGamma-aminobutyric acid A receptor alpha-5
Therapy Area/IndicationsDup15q syndromeSchizophreniaDown Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNewleos Therapeutics IncF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsDup15q syndromeSchizophreniaDown Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG